Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799646 | 0.79 | BCHE (0.45) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL11826578 | 0.79 | HSP90AB1 (0.44) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL22445351 | 0.78 | ALDH1A1 (0.40) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18758403 | 0.74 | BCHE (0.35) | MAPT | |
| SCHEMBL18758366 | 0.72 | MAPK1 (0.39) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL12374287 | 0.72 | HPGD (0.37) | HPGDGAA | |
| SCHEMBL23701884 | 0.71 | PGK1 (0.38) | — | |
| SCHEMBL18758466 | 0.71 | BCHE (0.32) | — | |
| SCHEMBL21877006 | 0.70 | KDM4E (0.37) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL23410551 | 0.70 | HDAC6 (0.47) | MAPTMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266983-B1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8349886-B2 | Nitrogenated 5-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8349886-B2 | Nitrogenated 5-membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2266983-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009128481-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190335-A1 | NITROGENATED 5-MEMBERED HETEROCYCLIC COMPOUND | GCKR, GCK, SLC5A1 | MAPT 4163/4885MEN1 2524/4885KMT2A 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.